**** updated on 4 April 2026 ****
Male in mid/late thirties, diagnosed with RRMS (2024), Ocrevus administered in January 2025, February 2025 and August 2025, had the premedication steroid Methylprednisolone on the second half-dose, but refused it at others.
Pre-Ocrevus…my hair was coarse and wavy, but could be dried into a relaxed style. I am mixed race: heritage Irish and Ugandanasian. Some family members have wiry coarse hair, so perhaps the medication exacerbated that underlying hair texture. I had some mild hair recession on my right temple, but nothing on the left-side.
I went on holiday in Sep 2024 before the first Ocrevus infusion, and when viewing holiday photos of my hair, it’s clear it was in better condition prior to this medication.
Post-Ocrevus and Methylprednisolone…there has been a drastic alteration in my hair texture as it became coarser and wiry with kinks. Furthermore, there has been drastic onset of hair recession, shedding, hair diffusion at left temple hairline. If there was underlying androgenetic hair recession, then I wonder if the Methylprednisolone steroid pre-med accelerated that if it alters DHT levels. I suspect it may be from hair follicle sensitivity to DHT. The hairline recession is considerable when compared to before medication.
After reading about other people’s experiences, it seems that both the Ocrevus and Methylprednisolone risk changing hair texture.
The hair texture change became noticeable at 6-8 months after the infusion: I first noticed the change when my hair brush was tugging in early September 2025 and my hair was appearing curly and wiry in photos.
Google AI says immuno-modulators (antineoplastic agents) can result in hair texture changes (either persistent or temporary depending on individual), Ocrevus and other MS medications fall under that medication classification as they are Monoclonal Antibody treatments.
The Methylprednisolone caused weight gain and fat redistribution to chin and midsection that remains unresolved after 13 months.
21 October 2025: Neurologist says that I am their first patient to mention the post Ocrevus hair texture change side effect.
28 October 2025: Thyroid normal, Thyroid Anti-body normal, Vitamin D low but in range, Vitamin B12 normal, Vitamin A, E and K normal.
28 November 2025: Iron and ferritin levels normal.
I have relayed these side effects to the MHRA.
On 9 Feb 2026, I received a formal letter from the Medical assessor at the MHRA who responded to my complaint about my side effects.
The MHRA said there are 61 reports of alopecia from Ocrevus, but nothing in relation to brittle hair texture (trichorrhexis), abnormal hair texture or hair injury.
I did not attend my Feb 2026 Ocrevus infusion and the NHS hospital delayed it until May, but I wish for a longer break from this medication for the reasons outlined, while I am concerned of immunosuppression. I developed mild acid reflux after this medication and aching/weakness in knees and legs.
The Neurologist mentioned the alternative options of Mavenclad or Briumvi, however they come with their own risks.
Unfortunately, the post-Ocrevus/Methylprednisolone hair texture change remains unresolved as of 22 March 2026.
If you have experienced hair texture changes or hair thinning, hair diffusion or hair recession from Ocrevus or the pre-medication steroid Methylprednisolone, then please share your experience or whether it’s reversible or not?
Shall endeavour to keep post updated.






